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group from the sham mntrols. CTnl release occurred both with and without
micronecrosis.
Conclusions: Among these serum markers, cTnl is the most sensitive for
detecting acute ischemic injury resulting from an acute reduction of resting
flow. cTni may be an useful marker in acute coronary syndromes, even
though an increase in cTnl does not necessarily indicate that necrosis has
developed.
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Isoforms in the Esrly Detection of Acute
Myocsrdisl Infarction
J. Ishii, H. Naruse, J.-h. Wang, S. Taga, M. Kinoshita, H. Kurokawa,
M. Nomura, Y.Watanabe, H. Hishida. Fujita f-feafthUniversim Toyoake,
Japan
Recently, heart fatty acid-binding protein (FABP) has been proposed as an
early marker of acute myocardial infarction (AMI). To evaluate the diagnostic
usefulness of FABP in the early diagnosis of AMI, we measured serum FABP
level and plasma CK-MB isoforms at admission in 134 consecutive patienta
within 6 houra (h) of the onset of symptoms (3.6+ 1.9 h). AMI was confirmed
in 80 patients by history, ECG changes and the pattern of serum CKMB
release and was excluded in 74 patients. The cut-off levels were as follows:
FABP,12 n~ml; CK-MB isoforms: MB2, 2.611.Mplus MBZMB1, 1.7.
Results: FABP, MB2 activity and MBZMB1 in patients with AMI were
higher than those in patients without AMI as showed below:
FABP(nglml) MB2 (lU/l) MB21MB1
WithAMI(n= 60) 169.6+ 310” 24.4* 37.6” 3.0+ 1.6”
WifhoutAMl(n =74) 24.2+46.6 2.2*2.2 1.6+ 1,0
(mean + SD, *p <0.01 vswithout AMl)
The diagnostic utility of these markers in AMI was as follows:
Sensitivity Specificity Predictiveaccuracy
FABP 7s%’ 76%* 7s%
CK-MSisoforms 61% 6S% 77”/0
(’p < 0.05vsCK-MBisoforms)
Conclusion: FABP, like CK-MB isoforms can provide a high level of accu-
racy for the diagnoaia of AMI within 6 houra of the onset of symptoms. For
the early detection of AMI, FABP may be more sensitive but less specific
than CK-MB isoforms.
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Very Early Visualization of Acute Myocardial
Infarction
G. Mariani, G. Villa, P.F.Rossettin, C. Motta, P.Spallarossa, G. Calcagno,
G.P.Bezente, C. Brunelli, S. Caponnetto, K.Y. Pak, J. Narula, H.W. Strauss,
B.A. Khaw. Univemify of Genoa, Italy Molecular Targeting TechnologyInc,
Malvem, PA, USA, Stanford Medical School, Stanford, CA, USA,
Nor?freestemUniversity Boston, MA, USA
Tc-99m labeled glucaric acid (TGIA) has been demonstrated to localize hy-
peracutely in experimental myocardial infarction (Ml). To determine whether
TGIA could be used in the ER for very eaffy imaging of Ml, phase I clinical
study of 16 patients (13 male, 3female; age range,24-73 yr.) presenting with
iachemic chest pain (CP) were injected with TGIA (900-1110 mBq) within 1
to 41 h of onset of CP. Anterior, 45QLAO and left lateral planar images (2–3
x 1Oscounts each) were obtained by 3 h after iv. injection. TI-201 or Tc-99m
MIBI perfusion images were obtained within next 46 h. Echocardiogrephy
was performed in all and pra-discharge coronav angiography in 1316 pa-
tients. Thirteen of the 16 patients received thrombolyfic therapy. Ml were
viauaiized with TGLA in 11/16 patients within 3 h of tracer administration in
both repeffused and non-reperfused infarcts. Five patients who had negative
TGIA scans, had received TGIA more than 9 h after CP when peak serum
CK levels had already been reached. TGIA acans repeated 4-8-week later
in 3 TGLA-positive and 2 TGLA-negative patients were negative.
The present study suggested that TGLA can identify zones of acute Ml
when the radiotracer is injected within 9 hof CPorbefore peak CK levels have
been reached in the sera. TGLA localized in repetfused or non-reperfused
Mi equally efficiently. Therefore, TGLA may provide a very early delineator
of Ml and may supplement other infarct-avid agents in the assessment of the
age of Ml.
E3105618 Diagnostic Utility of Troponin-TVersua Creatine
Kinase MB for Triage of Patients with Suspected
Infarction
A. Qamar, L. Bernstein, C.A. McPherson. Bridgeport /+ospita/and Ya/a
University Bridgeport, CT USA
We examined the potential utility of Cardiac Troponin-T (CTT) to diagnose
acute myocsrdial infarction (Ml) by performing a single CTT (monocional
antibody) assay on 267 consecutive patients (pts) (138 females, 129 males;
aged 16-92) in whom creatine kinase (CK) MB assays were ordered on
presentation. Final diagnosis was baaad on all available clinical data. The
duration of symptoms (DOS) was defined as the interval from symptom onset
until phlebotomy. Cl 60 pts with Ml, both CK-MB and CIT were elevated at
presentation in 26 (47% -mean DOS = 7.1 hra); in 23 (36%) CTT was
increased but CK-MB was not (DOS = 3.5 to 7 hra in 19 and >40 hra in 4).
Among 9pts with Ml, neither CTTnor CK-MB were elevated (DOS = 1 to 3.25
hra in6and242hrs in 1). Of26 pts with angina but no Ml, CTTwas elevated in
7 (9.7%) but CKMB was increased in none; 6 (66%) of the 7 pts with elevated
CTT had unstable angina and underwent angiography as compared with
6 (32?!.) of the 19 with normal CTT levels. Of the 161 pts with neither Ml
nor angina, initial CK-MB was elevated in 36 (20%); CTT was increased
in only 6 (3%-3 rhabdomyolysis, 2 cocaine intoxication, 1 “musculoskeletal
pain”). Overall, a single CIT assay on presentation had a positive predictive
value of 80% and a negative predictive value of 96% (for presence of Ml)
mmpared with 44% and 84% for CKMB drawn on presentation. We conclude
that CTT assay at presentation is superior to CKMB in correctly triaging pta
with suspected ML
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I 1057’-7[ AaaesementofLong Term Risk Following Vascular
Surgery - Development and Validation of A
Prognostic Scoring System in a Cohort of 1,046
Patients
G.J. L’ltalien, S.D. Paul, R.P.Cambfia, J.A. Leppo, R.C. Hendel,
L.A. Fleisher, M.C. Cohen, K.A. Brown, K.A. Eagle. Massachusetts Genera/
Hospital, Boston, MA, USA, Univ. of Massachusetts, Worceste< MA, USA,
Deaconess Hospital, Boston, MA, USA, Uniu of Vermont, Burlington ~
USA, Johns Hopkins Uniu, Ba/timore, MD, USA, Ya/eUniv, New Haven Ct,
USA, Northwestern UniK Chicago, ILL, USA, Uni~ of Michigan, Ann Arbq
Ml, USA
This study sought to develop and validate a long term risk prediction model
for vascular surgery candidates. From a cohort of 1,048 pts, from 5 medical
ctra, 700 were choaen at random to develop the model “training” set), and the
remaining 348 were used to validate it (“validation” set). The prediction model
permits sequential estimation of risk of fataihon-fatal Ml based on surgery
type (TYPE), TYPE +clinical markers (CLIN): (HxMI, Angina, CHF, Diabetes,
age > 70 y, prior CABG), and TYPE + CLIN + dipyridamole thallium data
(fixacfheveraible defects, iachemic ST changes). Model performance was
assessed by mmparing Kaplan-Meier estimates of event free survival for
both the training and validation sets at three levels of estimated risk (i.e.,
LOW, MOD, HIGH).
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